163 related articles for article (PubMed ID: 17475963)
1. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx.
Kim SY; Roh JL; Kim MR; Kim JS; Choi SH; Nam SY; Lee SW; Kim SB
J Nucl Med; 2007 May; 48(5):752-7. PubMed ID: 17475963
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.
Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W
Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
4. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
[TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
6. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ
Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
8. 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx.
Roh JL; Pae KH; Choi SH; Kim JS; Lee S; Kim SB; Nam SY; Kim SY
Eur J Surg Oncol; 2007 Aug; 33(6):790-5. PubMed ID: 17306956
[TBL] [Abstract][Full Text] [Related]
9. Utility of 18F-fluorodeoxyglucose positron emission tomography in the preoperative staging of squamous cell carcinoma of the oropharynx.
Kim MR; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Surg Oncol; 2007 Jun; 33(5):633-8. PubMed ID: 17391904
[TBL] [Abstract][Full Text] [Related]
10. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue.
Chung MK; Jeong HS; Son YI; So YK; Park GY; Choi JY; Hyun SH; Kim HJ; Ko YH; Baek CH
Ann Surg Oncol; 2009 Nov; 16(11):3111-7. PubMed ID: 19609618
[TBL] [Abstract][Full Text] [Related]
11. Impact of positron emission tomography with the use of fluorodeoxyglucose on response to induction chemotherapy in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.
Kawakita D; Masui T; Hanai N; Ozawa T; Hirakawa H; Terada A; Nishio M; Hosoi H; Hasegawa Y
Acta Otolaryngol; 2013 May; 133(5):523-30. PubMed ID: 23679812
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
15. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.
Seo S; Hatano E; Higashi T; Hara T; Tada M; Tamaki N; Iwaisako K; Ikai I; Uemoto S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):427-33. PubMed ID: 17255262
[TBL] [Abstract][Full Text] [Related]
17. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma.
Makino T; Miyata H; Yamasaki M; Fujiwara Y; Takiguchi S; Nakajima K; Higuchi I; Hatazawa J; Mori M; Doki Y
Surgery; 2010 Nov; 148(5):908-18. PubMed ID: 20378140
[TBL] [Abstract][Full Text] [Related]
18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
19. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]